Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir
Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR) announced that Lymphir has been assigned a unique, ...
Investing6d
Citius Pharma's LYMPHIR gains permanent J-code for billing
The J-code, J9161, will be effective starting April 1, 2025, and will facilitate the billing process for healthcare providers administering LYMPHIR for the treatment of adult patients with Stage I ...
Investing6d
Citius Pharma's LYMPHIR gains permanent J-code for billing
J-code for their drug LYMPHIR by the Centers for Medicare & Medicaid Services (CMS). The J-code, J9161, will be effective starting April 1, 2025, and will facilitate the billing process for healthcare ...
Morningstar6d
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Effective April 1, 2025, healthcare providers may use the permanent J-code, J9161 (Injection, denileukin diftitox-cxdl, for intravenous use, 1 microgram), when submitting claims for LYMPHIR.